NBO Pharma Inc.

BEDFORD, NY · Founded 2021 · CIK 0002103906 · Biotech · Private

Intranasal octreotide acetate formulation for idiopathic intracranial hypertension

nbopharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$7.6M
1 Form D · Jan 2026
8 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$7,640,217
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2538EIKONIZO THERAPEUTICS, INC.—$2.4M
2539Topos Bio, Inc.—$9.0M
2540Addition Therapeutics—$28M
2541NBO Pharma Inc.—$7.6M
2542Apriori Bio——
2543Trekka Therapeutics, LLC——
2544Rare Air Health, Inc.—$4.7M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Colin FosterDirector
  • Robert FriedmanDirector
  • Bard GeesamanDirector
  • Fredric PriceDirector · Executive Officer

Patents

USPTO · 0 granted of 2
  • Intranasal Formulations And Delivery Of Somatostatin Mimetics And Uses Thereofapplication
  • Methods And Threapeutic Combinations For Treating Idiopathic Intracranial Hypertension And Cluster Headachesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.